Beraprost modified release - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries

Drug Profile

Beraprost modified release - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries

Alternative Names: Beraprost controlled release; Beraprost MR - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries; Beraprost sustained release; Beraprost-SR; Berasus; Careload LA; TRK-100STP; YM 533

Latest Information Update: 20 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toray
  • Developer Astellas Pharma; Kaken Pharmaceutical; Toray
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Discontinued Renal failure; Spinal stenosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Aug 2014 Toray and Astellas complete a phase II/III trial in Renal failure in China, Hong Kong, Japan, Malaysia, South Korea, Taiwan and Thailand (NCT01090037)
  • 01 Feb 2014 Toray Industries completes a phase I trial in Renal impairment in Japan (NCT01443429)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top